ArticleDiscover oncology2025
Knowledge mapping and visualization of immune checkpoint inhibitor-related pneumonitis: a bibliometric analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025).Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have shown significant effectiveness in cancer treatment, yet checkpoint inhibitor-related pneumonitis (CIP) remains a severe immune-related adverse event (irAE). This study conducts a bibliometric analysis to identify potential research directions for CIP associated with ICIs in cancer therapy.
methodsWe retrieved articles published from 1991 to 2024 in the Web of Science Core Collection (WoSCC) database. Bibliometric tools, including VOSviewer, R-bibliometrix, and CiteSpace, were employed to analyze publication trends, contributing countries, journals, authors, and keywords.
resultsA total of 673 publications were analyzed, with the United States, China, and Japan identified as the primary contributors. The Lancet Oncology was the leading journal in terms of article volume and impact factor. Jarushka Naidoo had the highest H-index and publication output among authors. Recent research has focused on enhancing ICI efficacy in lung cancer while minimizing safety risks associated with adverse events through various drug combinations and therapeutic modifications. Key areas of emphasis include expanding ICI applications beyond melanoma and non-small cell lung cancer (NSCLC), managing severe CIPs and pre-existing pulmonary conditions, integrating radiotherapy and chemoradiotherapy with immunotherapy, and exploring corticosteroids and immunosuppressants.
conclusionAlthough the number of clinical trials on ICIs is increasing, effective strategies for preventing CIP and managing its symptoms are still lacking, and international collaboration in this research area is limited. This analysis offers a comprehensive overview of the current landscape, highlighting emerging research trends and key areas for future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.